AU2001275191A1 - Method for the purification of alphavirus replicon particles - Google Patents

Method for the purification of alphavirus replicon particles

Info

Publication number
AU2001275191A1
AU2001275191A1 AU2001275191A AU7519101A AU2001275191A1 AU 2001275191 A1 AU2001275191 A1 AU 2001275191A1 AU 2001275191 A AU2001275191 A AU 2001275191A AU 7519101 A AU7519101 A AU 7519101A AU 2001275191 A1 AU2001275191 A1 AU 2001275191A1
Authority
AU
Australia
Prior art keywords
purification
alphavirus replicon
methods
replicon particles
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275191A
Inventor
Maria Calderon-Cacia
Daniel Del La Vega Jr.
Thomas W. Dubensky Jr.
Catherine Greer
John M Polo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001275191A1 publication Critical patent/AU2001275191A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Powder Metallurgy (AREA)
  • Disintegrating Or Milling (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. In one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics
AU2001275191A 2000-05-31 2001-05-31 Method for the purification of alphavirus replicon particles Abandoned AU2001275191A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20837600P 2000-05-31 2000-05-31
US60208376 2000-05-31
PCT/US2001/018021 WO2001092552A2 (en) 2000-05-31 2001-05-31 Method for the purification of alphavirus replicon particles

Publications (1)

Publication Number Publication Date
AU2001275191A1 true AU2001275191A1 (en) 2001-12-11

Family

ID=22774372

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275191A Abandoned AU2001275191A1 (en) 2000-05-31 2001-05-31 Method for the purification of alphavirus replicon particles

Country Status (9)

Country Link
US (4) US6767699B2 (en)
EP (1) EP1285080B1 (en)
AT (1) ATE409749T1 (en)
AU (1) AU2001275191A1 (en)
CA (1) CA2410948C (en)
DE (1) DE60135983D1 (en)
DK (1) DK1285080T3 (en)
ES (1) ES2312447T3 (en)
WO (1) WO2001092552A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
EP1399183B1 (en) 2001-05-31 2010-06-30 Novartis Vaccines and Diagnostics, Inc. Chimeric alphavirus replicon particles
EP1432791B2 (en) * 2001-09-06 2013-10-23 Alphavax, Inc. Alphavirus replicon vector systems
US7195905B2 (en) * 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
AU2003229159B2 (en) 2002-04-30 2008-02-21 Oncolytics Biotech Inc. Improved viral purification methods
AU2003279770A1 (en) * 2002-10-01 2004-04-23 Novartis Vaccines And Diagnostics, Inc. Anti-cancer and anti-infectious disease compositions and methods for using same
AU2003297041B2 (en) * 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
WO2004055166A2 (en) 2002-12-13 2004-07-01 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
CN1791678A (en) * 2003-03-20 2006-06-21 阿尔法瓦克斯公司 Improved alphavirus replicons and helper constructs
WO2005007689A1 (en) * 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
AU2005245956B2 (en) * 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
EP2811027A1 (en) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
EP1736538A1 (en) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
KR100760525B1 (en) * 2006-04-13 2007-10-04 김재만 Kit and method for quantitatively detecting multiple pathogens without gene amplification
NZ575476A (en) 2006-09-12 2012-07-27 Alphavax Inc Alphavirus replicon particles encoding il- 12 as immunological adjuvants
US20090022760A1 (en) 2006-09-12 2009-01-22 Alphavax Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
AU2007317347B2 (en) * 2006-11-03 2014-02-06 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
PL2947149T3 (en) 2007-06-21 2018-09-28 Alphavax, Inc. Alphavirus replicon particles for use in vaccination
WO2010065414A1 (en) 2008-12-01 2010-06-10 Alphavax, Inc. Use of micrornas to control virus helper nucleic acids
AU2010203223B9 (en) 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
US10072307B1 (en) 2009-01-23 2018-09-11 Colorado State University Research Foundation Isolation of viruses using anionic resin beads
ES2540958T3 (en) 2009-04-08 2015-07-15 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
WO2012015908A2 (en) 2010-07-30 2012-02-02 Millipore Corporation Chromatography media and method
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
BR112013032410A2 (en) 2011-06-24 2017-01-17 Epitogenesis Inc pharmaceutical compositions comprising a combination of selection vehicles, vitamins, tannins and flavonoids as antigen specific immunomodulators
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
JP6652554B2 (en) 2014-09-02 2020-02-26 イー・エム・デイー・ミリポア・コーポレイシヨン High surface area fiber media with nanofibrillated surface features
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
KR102162753B1 (en) 2014-12-08 2020-10-07 이엠디 밀리포어 코포레이션 Mixed bed ion exchange adsorber
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017109223A1 (en) 2015-12-23 2017-06-29 Valneva Se Virus purification
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
KR20200056982A (en) 2017-09-21 2020-05-25 발네바 에스이 Method of producing a pharmaceutical composition comprising the immunogenic chikungunya virus CHIKV-delta 5NSP3
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466788A (en) * 1985-03-07 1995-11-14 Mycogen Plant Science, Inc. Subgenomic promoter
ES8800988A1 (en) 1985-04-05 1987-12-16 Meloy Lab Sustained high-level production of recombinant human gamma interferon using a bovine papillomavirus vector.
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
WO1988000472A1 (en) 1986-07-23 1988-01-28 Aphton Corporation Immunogens and improved methods of making immunogens
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5093239A (en) 1988-05-02 1992-03-03 Eastman Kodak Company Reagents for detecting oxidase positive microorganisms
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5026686A (en) 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
SE9003978D0 (en) 1990-12-13 1990-12-13 Henrik Garoff DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
DE4315109A1 (en) 1993-05-06 1994-11-10 Inst Pflanzengenetik & Kultur Method and vector construct for increasing expression of transgenes
ATE250670T1 (en) 1993-07-06 2003-10-15 Univ Nice Sophia Antipolis VECTOR CONTAINING A VIRUS GENE TRANSCRIPTED AT ARN-POLYMERASE-III
US5837503A (en) 1993-07-07 1998-11-17 Universite De Nice-Sophia-Antipolis Vector containing viral gene transcribed by RNA polymerase III and methods for use
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
IL112371A0 (en) 1994-01-25 1995-03-30 Res Dev Foundation A novel protein from aedes albopictus cells and methods for its use
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
US5532154A (en) 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
SE9401091D0 (en) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
SE9401709D0 (en) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
EP0847442A1 (en) * 1995-08-30 1998-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
AU2051297A (en) 1996-02-15 1997-09-02 Chiron Corporation Gene therapy method using fgf-5
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
ATE386811T1 (en) 1996-04-05 2008-03-15 Novartis Vaccines & Diagnostic ALPHAVIRUS VECTOR WITH A REDUCED INHIBITION OF THE SYNTHESIS OF CELL MACROMOLECLES
WO1997044446A1 (en) 1996-05-24 1997-11-27 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US5843712A (en) 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
US6489167B1 (en) 1996-09-25 2002-12-03 The Government Of The United States As Represented By The Secretary Of The Department Of Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors
JP2001501483A (en) 1996-10-10 2001-02-06 ガロフ，ヘンリク Alphavirus-retrovirus vector
AU7637796A (en) 1996-12-09 1998-07-03 James Edwin Bailey Expression of active interferon beta 1 using recombinant rna replicons
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6261570B1 (en) 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
WO1999009192A1 (en) 1997-08-15 1999-02-25 Inex Pharmaceuticals Corporation Semliki forest virus vectors for gene transfer into non-endothelial cardiovascular cells
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
EP1017797B1 (en) 1997-09-24 2005-06-22 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
EP1034289A1 (en) 1997-11-14 2000-09-13 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
JP3835669B2 (en) 1997-11-14 2006-10-18 サノフィ パスツ−ル リミテッド Alphavirus vector
AU1710699A (en) 1997-12-18 1999-07-05 G.D. Searle & Co. Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity

Also Published As

Publication number Publication date
ES2312447T3 (en) 2009-03-01
WO2001092552A2 (en) 2001-12-06
US20100055128A1 (en) 2010-03-04
EP1285080B1 (en) 2008-10-01
CA2410948C (en) 2012-07-17
ATE409749T1 (en) 2008-10-15
DE60135983D1 (en) 2008-11-13
DK1285080T3 (en) 2008-12-01
US20020015945A1 (en) 2002-02-07
WO2001092552A3 (en) 2002-05-23
US20050112752A1 (en) 2005-05-26
EP1285080A2 (en) 2003-02-26
US6767699B2 (en) 2004-07-27
CA2410948A1 (en) 2001-12-06
US20120231526A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
AU2001275191A1 (en) Method for the purification of alphavirus replicon particles
EP1399183A4 (en) Chimeric alphavirus replicon particles
HU9603155D0 (en) Papillomavirus vaccines
MXPA06013124A (en) Tc-83-derived alphavirus vectors, particles and methods.
PT1651666E (en) Alphavirus-based cytomegalovirus vaccines
IL153705A0 (en) Method of making particles for use in a pharmaceutical composition
WO2002029045A3 (en) Method for the production of vitamin k-dependent proteins
WO2001034801A3 (en) Recombinant gelatin in vaccines
DE60129695D1 (en) INCREASING IMMUNE RESPONSES MEDIATED BY ANTIBODY CYTOKIN FUSION PROTEINS BY COMBINED TREATMENT WITH MEDICAMENTS FOR INCREASING IMMUNOCYTIC INJECTION
WO2004087896A3 (en) Hepatocyte differentiation of stem cells
AU2002310321A1 (en) Compositions and methods for high-level, large-scale production of recombinant proteins
IL172634A0 (en) Agent for inhibiting membrane virus reproduction, method for the production thereof pharmaceutical composition and method for inhibiting viral infections
WO2006041897A3 (en) Chimeric vectors
WO2004050680A3 (en) Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
AU2001259217A1 (en) Human pellino polypeptides
AU2002216968A1 (en) Plasma fraction containing bikunin, method for the production thereof and use of the same
WO2008027560A3 (en) Holin-enhanced vaccines and reagents, and methods of use thereof
DK1423525T3 (en) Recombinant MVA capable of expressing HCV structural antigens
AU2003258611A1 (en) Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines
DE69728447D1 (en) CHANGED SMALL RNA VIRUSES
FI20020375A (en) Method for generating virus-like particles (VKP), plasmid construct and uses of the method
WO2004056979A3 (en) Recombinant virus production for the manufacturing of vaccines
AU2001278139A1 (en) Enhanced replication of hcv rna
AU2003234712A1 (en) Differentially expressed genes involved in angiogenesis, the proteins encoded thereby, and methods of using the same
Baronova et al. Ion distribution according to ionization degrees in pinch plasma; Raspredelenie ionov po stepenyam ionizatsii v plazme pincha